---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-019590"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T11:36:05.842621+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aquestive CEO Keith Kendall departs; COO Daniel Barber named President & CEO

## Summary
- Keith Kendall leaves as President, CEO, and Board member effective May 17, 2022.
- Daniel Barber, former COO (since May 2019), appointed President, CEO, and Class I Director.
- Kendall receives severance: $262,500 accelerated first three installments plus monthly payments, and $10,000/month consulting fee through Dec 2022.
- Kendall will serve as consultant to assist in management transition through end of 2022.
- Company states Kendall's departure is unrelated to strategy, operations, or financial condition.

## SEC filing metadata
- accession: 0001140361-22-019590
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/brhc10037837_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-019590
- JSON: https://secwatch.observer/filing/0001140361-22-019590.json
- Plain text: https://secwatch.observer/filing/0001140361-22-019590.txt

## Key facts
- Executive change
  Daniel Barber was appointed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Effective May 17, 2022, the Board appointed Daniel Barber, Senior Vice President and Chief Operating Officer of the Company, to the position of President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm
- Executive change
  Keith J. Kendall departed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..
  - Action: leaving
  - Role: President and Chief Executive Officer
  source text: On May 17, 2022, Aquestive Therapeutics, Inc. (the “Company”) announced that Keith J. Kendall, President and Chief Executive Officer of the Company, is leaving the Company and Board of Directors (the “Board”) effective May 17, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm
- Executive change
  Daniel Barber was appointed as Class I Director at Aquestive Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: In addition, the Board appointed Mr. Barber to fill the vacancy on the Board due to Mr. Kendall’s departure, to serve as a Class I Director with a term expiring at the Company’s 2022 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.